Recurrent Ovarian Epithelial Cancer Clinical Trial
Official title:
A Phase I/IIb Study of Recombinant ALVAC(2)-NY-ESO-1 (M)/TRICOM in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
This partially randomized phase I/IIb trial studies the side effects vaccine therapy and indoleamine 2,3-dioxygenase (IDO1) inhibitor 4-amino-1,2,5-oxadizaole-3-carboximidamide (INCB024360) and to see how well they work in treating patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in remission. Vaccines made from gene-modified virus may help the body build an effective immune response to kill tumor cells. IDO1 inhibitor INCB024360 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy with IDO1 inhibitor INCB024360 may be an effective treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
PRIMARY OBJECTIVES:
I. To determine the safety of fixed doses of the modified canarypox vector
(ALVAC[2])-cancer/testis antigen 1B (NY-ESO-1) (M)/triad of costimulatory molecules (TRICOM)
vaccine in combination with INCB024360 (IDO1 inhibitor INCB024360). (Phase I) II. To
evaluate toxicity as defined by National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE) version 4.0. (Phase I) III. To determine the progression free
survival (PFS) using standard imaging response (Response Evaluation Criteria in Solid Tumors
[RECIST] 1.1) criteria. (Phase IIb)
SECONDARY OBJECTIVES:
I. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing
NY-ESO-1 specific cellular and humoral immunity in peripheral blood NY-ESO-1 specific CD8+
and CD4+ T cells.
II. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing
NY-ESO-1 specific cellular and humoral immunity in peripheral blood NY-ESO-1 specific
antibodies.
III. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing
NY-ESO-1 specific cellular and humoral immunity in peripheral blood frequency of
CD4+CD25+FOXP3+ regulatory T cells.
IV. To determine the effectiveness of INCB024360 on enhancing vaccine efficacy by assessing
NY-ESO-1 specific cellular and humoral immunity in pharmacokinetics (PK) of IDO in relation
to T cell frequency and function in correlation with PFS.
OUTLINE: This is a Phase I study followed by a randomized Phase IIb study.
PHASE I: Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine subcutaneously (SC) on day 1
and IDO1 inhibitor INCB024360 orally (PO) twice daily (BID) on days 1-28. Treatment repeats
every 28 days for up to 6 courses in the absence of disease progression or unacceptable
toxicity.
PHASE IIb: Patients are randomized to 1 of 4 arms.
ARM A: Patients receive no treatment.
ARM B: Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
ARM C: Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor
INCB024360 PO BID on days 1-28.
ARM D: Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
In all arms, treatment repeats every 28 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up at 6 weeks; at 3, 6, and 12
months; and then annually for up to 15 years.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00390234 -
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
|
Phase 2 | |
| Terminated |
NCT00091195 -
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
|
Phase 2 | |
| Completed |
NCT00096395 -
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT00026091 -
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
|
Phase 2 | |
| Terminated |
NCT01962948 -
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
| Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A | |
| Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00093496 -
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
|
Phase 2 | |
| Completed |
NCT00132067 -
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
|
Phase 2 | |
| Completed |
NCT00275028 -
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 2 | |
| Completed |
NCT00006942 -
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 2 | |
| Completed |
NCT00004032 -
Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT00023712 -
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
|
Phase 2 | |
| Terminated |
NCT01249443 -
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
|
Phase 1 | |
| Completed |
NCT02046421 -
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT00028535 -
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01747798 -
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
Early Phase 1 | |
| Completed |
NCT01652794 -
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
|
Phase 1 | |
| Withdrawn |
NCT01558778 -
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
|
N/A |